Spravato (esketamine) is a nasal spray approved by the FDA for treatment-resistant depression (TRD) in adults. It is a derivative of ketamine and works as a fast-acting antidepressant by modulating glutamate levels in the brain, which is believed to play a key role in mood regulation. Administered under the supervision of a healthcare provider, Spravato is typically used in conjunction with an oral antidepressant. Its rapid onset of action can provide relief from depressive symptoms within hours, making it a critical option for individuals who have not responded to traditional therapies. Common side effects may include dissociation, sedation, and increases in blood pressure, necessitating monitoring during administration.